DISCOVERY AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF SULFONAMIDE ETA-SELECTIVE ANTAGONISTS

被引:39
作者
STEIN, PD
FLOYD, DM
BISAHA, S
DICKEY, J
GIROTRA, RN
GOUGOUTAS, JZ
KOZLOWSKI, M
LEE, VG
LIU, ECK
MALLEY, MF
MCMULLEN, D
MITCHELL, C
MORELAND, S
MURUGESAN, N
SERAFINO, R
WEBB, ML
ZHANG, R
HUNT, JT
机构
[1] BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT CHEM,PRINCETON,NJ 08543
[2] BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT SOLID STATE CHEM,PRINCETON,NJ 08543
[3] BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT CARDIOVASC BIOCHEM,PRINCETON,NJ 08543
[4] BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT PHARMACOL,PRINCETON,NJ 08543
[5] BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT BIOMOLEC SCREENING,WALLINGFORD,CT 06492
关键词
D O I
10.1021/jm00008a013
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Random screening of compounds in an ETA receptor binding assay led to the discovery of a class of benzenesulfonamide ligands. Optimization led to the development of 5-amino-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamides which were functional antagonists. Structural features which were important to activity included a 1,5-substitution pattern on the naphthalene ring; a sulfonamide NH with a pK value < 7; an amine, preferably with alkyl substituents, at the 5-position; and methyl groups on both the 3- and 4-positions of the isoxazole.
引用
收藏
页码:1344 / 1354
页数:11
相关论文
共 54 条
[1]  
ANTONACCIO MJ, 1993, J PHARMACOL EXP THER, V266, P125
[2]   CLONING AND EXPRESSION OF A CDNA-ENCODING AN ENDOTHELIN RECEPTOR [J].
ARAI, H ;
HORI, S ;
ARAMORI, I ;
OHKUBO, H ;
NAKANISHI, S .
NATURE, 1990, 348 (6303) :730-732
[3]  
BAGLEY SW, 1994, Patent No. 5334598
[4]   STRUCTURE DETERMINATION OF SUBSTITUTED NAPHTHALENES BY NUCLEAR OVERHAUSER ENHANCEMENT MEASUREMENTS [J].
BECKER, D ;
LOEWENTHAL, HJE .
TETRAHEDRON, 1992, 48 (12) :2515-2522
[5]   Studies in chemotherapy. VII. A theory of the relation of structure to activity of sulfanilamide type compounds [J].
Bell, PH ;
Roblin, RO .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1942, 64 :2905-2917
[6]   A SPECIFIC ENDOTHELIN SUBTYPE-A RECEPTOR ANTAGONIST PROTECTS AGAINST INJURY IN RENAL-DISEASE PROGRESSION [J].
BENIGNI, A ;
ZOJA, C ;
CORNA, D ;
ORISIO, S ;
LONGARETTI, L ;
BERTANI, T ;
REMUZZI, G .
KIDNEY INTERNATIONAL, 1993, 44 (02) :440-444
[7]  
Burow K. W. J., 1987, US Patent, Patent No. [4,636,243, 4636243]
[8]   THE SYNTHESIS OF MEDIUM-SIZED CYCLIC LACTAMS BY THE INTRAMOLECULAR FRIEDEL-CRAFTS CYCLIZATION OF ISOCYANATES - FORMATION OF NOVEL PYRAZOLO[3,4-C]BENZOLACTAMS [J].
BUTLER, DE ;
ALEXANDER, SM .
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1982, 19 (05) :1173-1177
[9]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[10]   PATHOPHYSIOLOGICAL ROLE OF ENDOTHELIN REVEALED BY THE 1ST ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST [J].
CLOZEL, M ;
BREU, V ;
BURRI, K ;
CASSAL, JM ;
FISCHLI, W ;
GRAY, GA ;
HIRTH, G ;
LOFFLER, BM ;
MULLER, M ;
NEIDHART, W ;
RAMUZ, H .
NATURE, 1993, 365 (6448) :759-761